{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T04:12:36Z","timestamp":1743307956766,"version":"3.40.3"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T00:00:00Z","timestamp":1254182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>The aim of this study was to evaluate the impact of an enfuvirtide-based antiretroviral (ARV) regimen on the management of immunosuppression and follow-up in hepatitis C virus (HCV)\/hepatitis B virus (HBV)\/human immunodeficiency virus (HIV)\u2013coinfected liver transplant patients in comparison with a lopinavir\/ritonavir-based ARV regimen. Tacrolimus and cyclosporine trough concentrations were determined at a steady state during 3 periods: after liver transplantation without ARV treatment (period 1), at the time of ARV reintroduction (period 2), and 2 to 3 months after liver transplantation (period 3). The findings for 22 HIV-coinfected patients were compared (18 with HCV and 4 with HBV); 11 patients were treated with enfuvirtide and were matched with 11 lopinavir\/ritonavir\u2013exposed patients. During period 1, tacrolimus and cyclosporine A doses were 8 and 600 mg\/day, respectively, and the trough concentrations were within the therapeutic range in both groups. In period 2, the addition of lopinavir\/ritonavir to the immunosuppressant regimen enabled a reduction in the dose of immunosuppressants required to maintain trough concentrations within the therapeutic range (to 0.3 mg\/day for tacrolimus and 75 mg\/day for cyclosporine). Immunosuppressant doses were not modified by the reintroduction of enfuvirtide, there being no change in the mean trough concentrations over the 3 periods. CD4 cell counts remained at about 200 cells\/mm. The HIV RNA viral load remained undetectable. Both groups displayed signs of mild cytolysis and cholestasis due to the recurrence of HCV, whereas no renal insufficiency was observed. Enfuvirtide is an attractive alternative to standard ARV therapy, facilitating the management of drug-drug interactions shortly after liver transplantation. Moreover, the lack of liver toxicity renders this drug valuable in the event of a severe HCV recurrence. Liver Transpl 15:1330\u20131335, 2009. \u00a9 2009 AASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.21818","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T13:54:22Z","timestamp":1254232462000},"page":"1336-1342","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Enfuvirtide: A safe and effective antiretroviral agent for human immunodeficiency virus\u2013infected patients shortly after liver transplantation"],"prefix":"10.1097","volume":"15","author":[{"given":"Elina","family":"Teicher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chadi","family":"Abbara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Charles","family":"Duclos-Vall\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Bonhomme-Faivre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Desbois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Vittecoq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-27-20250326","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jhep.2008.02.009","article-title":"Are HIVinfected patients candidates for liver transplantation?","volume":"48","author":"Samuel","year":"2008","journal-title":"J Hepatol"},{"key":"R2-27-20250326","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/01.TP.0000075973.73064.A6","article-title":"Kidney and liver transplantation in human immunodeficiency virusinfected patients: a pilot safety and efficacy study.","volume":"76","author":"Stock","year":"2003","journal-title":"Transplantation"},{"key":"R3-27-20250326","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/lt.20776","article-title":"Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation.","volume":"12","author":"Terrault","year":"2006","journal-title":"Liver Transpl"},{"key":"R4-27-20250326","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.21990","article-title":"Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus.","volume":"47","author":"DuclosVallee","year":"2008","journal-title":"Hepatology"},{"key":"R5-27-20250326","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jhep.2004.11.029","article-title":"Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIVHCV coinfected patients.","volume":"42","author":"DuclosVallee","year":"2005","journal-title":"J Hepatol"},{"key":"R6-27-20250326","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1111\/j.1600-6143.2006.01546.x","article-title":"Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C.","volume":"6","author":"de Vera","year":"2006","journal-title":"Am J Transplant"},{"key":"R7-27-20250326","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS SocietyUSA panel.","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"R9-27-20250326","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jac\/dkl524","article-title":"Liver toxicity induced by nonnucleoside reverse transcriptase inhibitors.","volume":"59","author":"Rivero","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R10-27-20250326","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenzcontaining antiretroviral therapy: role of hepatitis C and B infections.","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"R11-27-20250326","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1310\/N4VT-3E9U-4BKN-CRPW","article-title":"Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.","volume":"4","author":"MartinCarbonero","year":"2003","journal-title":"HIV Clin Trials"},{"key":"R12-27-20250326","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","article-title":"Hepatotoxicity in HIV1infected patients receiving nevirapinecontaining antiretroviral therapy.","volume":"15","author":"Martinez","year":"2001","journal-title":"AIDS"},{"key":"R13-27-20250326","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00002030-200403260-00008","article-title":"Longterm safety and durable antiretroviral activity of lopinavirritonavir in treatmentnaive patients: 4 year followup study.","volume":"18","author":"Hicks","year":"2004","journal-title":"AIDS"},{"key":"R14-27-20250326","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/135965350200700305","article-title":"Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitorexperienced HIV1infected patients receiving lopinavirritonavir therapy.","volume":"7","author":"Kempf","year":"2002","journal-title":"Antivir Ther"},{"issue":"suppl 2","key":"R15-27-20250326","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1086\/381444","article-title":"Druginduced liver injury associated with antiretroviral therapy that includes HIV1 protease inhibitors.","volume":"38","author":"Sulkowski","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R16-27-20250326","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","article-title":"Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and Pglycoprotein: implications for drug delivery and activity in cancer chemotherapy.","volume":"13","author":"Wacher","year":"1995","journal-title":"Mol Carcinog"},{"key":"R17-27-20250326","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-3659(99)00034-6","article-title":"Intestinal MDR transport proteins and P450 enzymes as barriers to oral drug delivery.","volume":"62","author":"Benet","year":"1999","journal-title":"J Control Release"},{"key":"R18-27-20250326","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1124\/jpet.102.044719","article-title":"In vivo modulation of intestinal CYP3A metabolism by Pglycoprotein: studies using the rat singlepass intestinal perfusion model.","volume":"305","author":"Cummins","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R19-27-20250326","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2165\/00003088-200443050-00003","article-title":"Pharmacokinetic enhancement of protease inhibitor therapy.","volume":"43","author":"King","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R20-27-20250326","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1053\/jlts.2003.50171","article-title":"Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients.","volume":"9","author":"Jain","year":"2003","journal-title":"Liver Transpl"},{"key":"R21-27-20250326","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00003088-200746110-00002","article-title":"Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV coinfected liver transplant recipients in the ANRS HC08 study.","volume":"46","author":"Teicher","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"R22-27-20250326","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/j.1600-6143.2007.02007.x","article-title":"Immunosuppressant pharmacokinetics and dosing modifications in HIV1 infected liver and kidney transplant recipients.","volume":"7","author":"Frassetto","year":"2007","journal-title":"Am J Transplant"},{"key":"R23-27-20250326","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/lt.20165","article-title":"Management of drugtodrug interactions between cyclosporine A and the proteaseinhibitor lopinavirritonavir in livertransplanted HIVinfected patients.","volume":"10","author":"Vogel","year":"2004","journal-title":"Liver Transpl"},{"key":"R24-27-20250326","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.TP.0000165111.09687.4E","article-title":"Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virusinfected liver and kidney transplant recipients.","volume":"80","author":"Frassetto","year":"2005","journal-title":"Transplantation"},{"key":"R25-27-20250326","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/135965350501000413","article-title":"Therapeutic drug monitoring and drugdrug interactions involving antiretroviral drugs.","volume":"10","author":"Boffito","year":"2005","journal-title":"Antivir Ther"},{"key":"R26-27-20250326","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1523-1755.2004.00772.x","article-title":"Antiretroviral and immunosuppressive drugdrug interactions: an update.","volume":"66","author":"Izzedine","year":"2004","journal-title":"Kidney Int"},{"key":"R27-27-20250326","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drugresistant HIV1 in Europe and Australia.","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"key":"R28-27-20250326","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/01.qai.0000185314.56556.c3","article-title":"Durable efficacy of enfuvirtide over 48 weeks in heavily treatmentexperienced HIV1infected patients in the T20 versus optimized background regimen only 1 and 2 clinical trials.","volume":"40","author":"Nelson","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R29-27-20250326","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1592\/phco.24.2.198.33141","article-title":"Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection.","volume":"24","author":"Hardy","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R30-27-20250326","first-page":"139","article-title":"Enfuvirtide, the first fusion inhibitor to treat HIV infection.","volume":"7","author":"Poveda","year":"2005","journal-title":"AIDS Rev"},{"key":"R31-27-20250326","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.510250328","article-title":"Banff schema for grading liver allograft rejection: an international consensus document.","volume":"25","year":"1997","journal-title":"Hepatology"},{"key":"R33-27-20250326","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1089\/apc.2006.0113","article-title":"Risk factors for grade 34 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy.","volume":"21","author":"Chihrin","year":"2007","journal-title":"AIDS Patient Care STDS"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.21818","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.21818","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-200910000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T15:51:39Z","timestamp":1743263499000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-200910000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.21818","relation":{},"ISSN":["1527-6465"],"issn-type":[{"type":"print","value":"1527-6465"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}